Dr. Rezvani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Drive
Stanford, CA 94305Phone+1 650-723-0822- Is this information wrong?
Summary
- I am a physician and clinical researcher at Stanford University, specializing in hematopoietic cell transplantation and cellular therapy.
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007
- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
- Duke University HospitalResidency, Internal Medicine, 2001 - 2004
- Lewis Katz School of Medicine at Temple UniversityClass of 2001
Certifications & Licensure
- CA State Medical License 2014 - 2025
- WA State Medical License 2004 - 2015
- NC State Medical License 2001 - 2004
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Start of enrollment: 2006 Dec 01
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2009 Feb 01
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.Rezvani, A. R., Liora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, Bita Sahaf, Hrishi Srinagesh, Parveen Shiraz, Neha Agarwal, Mark Hamilton, Courtney Erickson, ...> ;Leukemia. 2024 May 1
- Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD.Rezvani, A. R., Cameron S Bader, Anna Pavlova, Robert Lowsky, Lori S Muffly, Parveen Shiraz, Sally Arai, Laura J Johnston, Andrew R Rezvani, Wen-Kai Weng, David B Mikl...> ;Blood Advances. 2024 Mar 12
- 5 citationsASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.Zurko, J. C., Rezvani, A. R., Narendranath Epperla, Ambuj Kumar, Syed A Abutalib, Farrukh T Awan, Yi-Bin Chen, Ajay K Gopal, Jennifer Holter-Chakrabarty, Natasha Kekre...> ;Transplantation and Cellular Therapy. 2023 Sep 1
- Join now to see all
Abstracts/Posters
- Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel AgentsAndrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Com...Andrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
- Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
- Nevada Cancer Survivor Found to Have Two Different Sets of DNA After Bone Marrow Transplant 4 Years AgoDecember 10th, 2019
- After Bone Marrow Transplant, Patient's Blood Contains Only Donor's DNA: Three Months After a Nevada Man Received a Bone Marrow Transplant, Tests Revealed the DNA in His Blood Had Been Replaced by the DNA of His Donor, a Man He Barely Knew, According t...December 9th, 2019
Hospital Affiliations
- Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: